Guardant Health (GH) Director Azar Alex M II Sells $11K of Stock

Director Azar Alex M II sold 69 shares of Guardant Health, Inc. (NasdaqGS: GH) on October 14, 2026, for about $11,032. The shares were sold at a price of $159.89 each, as reported in a Form 4 filing with the SEC. This sale was made under a planned trading arrangement.

Other Institutional Activity in Guardant Health

Blackrock Inc. reduced its holdings by 3,930,468 shares, ending with 7,622,935 shares worth about $1.21 billion. Price (T.Rowe) Associates Inc. trimmed its stake by 508,498 shares, bringing its total to 6,514,952 shares valued at approximately $1.03 billion. Vanguard Capital Management LLC grew its holdings by 131,607 shares, bringing its total to 5,755,857 shares worth about $912.9 million. FMR, LLC increased its position by 1,372,274 shares, ending with 5,488,272 shares valued at roughly $870.4 million. Vanguard Portfolio Management LLC decreased its stake by 392,321 shares, holding a total of 5,445,785 shares worth about $863.7 million.

Guardant Health, Inc. Stock Down 3.6%

As of October 16, 2026, Guardant Health's stock trades recently around $159.97, which is about 4.8% below its 50-day moving average of $168.06. The stock is also 16.3% below its 52-week high of $191.05, but it is significantly above its 52-week low of $64.00. The mean price target from analysts stands at $201.64, suggesting potential upside from the current price.

Recent Earnings

For the trailing twelve months, Guardant Health reported revenue of about $1.18 billion, reflecting a year-over-year growth of 44.3%. However, the company posted a net margin of -38.3%, indicating it has not been profitable recently. The next earnings report is scheduled for November 5, 2026.

Insider Buying and Selling at Guardant Health, Inc.

Recently, Co-Chief Executive Officer Amirali Talasaz sold 111,804 shares on June 26, 2026, but also bought shares earlier, showing a mix of buying and selling activity. This includes another purchase of 143,028 shares on June 29, 2026. These transactions indicate a complex pattern of insider trading at the company.

Analysts Set New Price Targets

On September 8, 2026, Rothschild & Co initiated coverage on Guardant Health with a Buy rating and a price target of $203. On September 9, UBS maintained its Buy rating with a target of $225, followed by Guggenheim on October 1, which also kept a Buy rating but adjusted its target to $200. Barclays and Morgan Stanley maintained their Overweight ratings with new targets of $220 and $200, respectively, on October 7 and October 13.

About Guardant Health

Guardant Health, Inc. is a precision oncology company based in Palo Alto, CA. It specializes in providing blood and tissue tests, along with data sets, to help in cancer diagnostics and treatment. The company's focus on innovative testing solutions is crucial as it navigates the competitive healthcare landscape.

Bottom Line

Investors should keep an eye on Guardant Health's upcoming earnings report on November 5, 2026, which could provide further insights into its financial performance. With a mix of insider selling and positive analyst ratings, the stock is worth monitoring closely.